Key Metrics
4.5
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.01 - 0.05
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.89
5-Year SI
5-year SI
- 0.87 2-year SI
- 0.89 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q3
Oncology
SJR
- Q3 Oncology
- Q3 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.19
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
3 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Cancer
- Metabolism
- Overall survival
- Lung cancer
- Cancer genome
- Lymph node
- Biopsy
- Machine learning
- Radiation
- Progression-free survival
- Extracellular vesicles
- Immunotherapy
- Chemoradiotherapy
- Confidence interval
- Toxicity
- Breast cancer
- Hepatocellular carcinoma
- Lung
- Extracellular matrix
- Chemotherapy
Journal Specifications
| Overview | |
| Publisher | FRONTIERS MEDIA SA |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2950 |
| Publication Time | 14 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 14 |
| Article Processing Charges | USD 2950 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
Planning to publish in Frontiers in Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Moving from conventional to adaptive risk stratification for oropharyngeal cancer.
- 14 Mar 24
- Frontiers in oncology
-
Full paper
Effectiveness of sigmoidoscopy or colonoscopy screening on colorectal cancer incidence and mortality: a systematic review and meta-analysis of randomized controlled trial.
- 14 Mar 24
- Frontiers in oncology
-
Full paper
Machine learning models based on quantitative dynamic contrast-enhanced MRI parameters assess the expression levels of CD3+, CD4+, and CD8+ tumor-infiltrating lymphocytes in advanced gastric carcinoma.
- 14 Mar 24
- Frontiers in oncology
-
Full paper
Exploration of the molecular biological mechanisms and review of postoperative radiotherapy cases in tenosynovial giant cell tumors.
- 14 Mar 24
- Frontiers in oncology
-
Full paper
Prognostic nomogram in patients with right-sided colon cancer after colectomy: a surveillance, epidemiology, and end results-based study.
- 14 Mar 24
- Frontiers in oncology
-
Full paper
Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report.
- 14 Mar 24
- Frontiers in oncology
Scite analysis
Powered by scite_
26.6k articles received 242.2k citations see all
- 7,625 Supporting
- 230,919 Mentioning
- 919 Contrasting
Editorial notices
- 91 Retractions
- 0 Withdrawals
- 332 Corrections
- 282 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
46%
4 to 6 months
44%
7 to 9 months
8%
Above 9 months
3%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has Frontiers in Oncology been actively publishing?
Frontiers in Oncology has been in operation since 2011 till date.
What is the publishing frequency of Frontiers in Oncology ?
Frontiers in Oncology published with a Continuous publication frequency.
How many articles did Frontiers in Oncology publish last years ?
In 2023, Frontiers in Oncology published 4469 articles.
What is the eISSN & pISSN for Frontiers in Oncology ?
For Frontiers in Oncology,eISSN is 2234-943X and pISSN is2234-943X.
What is Citescore for Frontiers in Oncology ?
Citescore for Frontiers in Oncology is 4.5.
What is SNIP score for Frontiers in Oncology ?
SNIP score for Frontiers in Oncology is 1.19.
What is the SJR for Frontiers in Oncology ?
SJR for Frontiers in Oncology is Q3.
Who is the publisher of Frontiers in Oncology ?
FRONTIERS MEDIA SA is the publisher of Frontiers in Oncology.